---
document_datetime: 2023-09-21 19:12:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/xelevia-epar-procedural-steps-taken-authorisation_en.pdf
document_name: xelevia-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3973534
conversion_datetime: 2025-12-29 19:40:38.311535
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Merck  Sharp  &amp;  Dohme  Ltd.  submitted  on  8  September  2006  an  application  for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Xelevia,  through  the centralised  procedure  falling  within  the  Article  3(1)  and  point  3  of  Annex  of  Regulation  (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 13 October 2005

The legal basis for this application refers to:

## A - Centralised / Article 8(3) / New active substance.

The application submitted is a complete dossier: composed of administrative information, complete quality  data,  non-clinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or bibliographic literature substituting/supporting certain tests or studies.

Xelevia is a duplicate application of Januvia.

## Scientific Advice:

The  applicant  received  Scientific  Advice  for  Januvia  from  the  CHMP  on  22  January  2004  and  on 24 June 2004. The Scientific Advice pertained to preclinical and clinical aspects of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Frits Lekkerkerker

Co-Rapporteur:

Harald Enzmann

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 06 July 2006.
- The procedure started on 17 September 2006. Start date was in alignment with the re-start of the Januvia procedure after the submission of the responses to the D120 LoQ.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 20 October 2006 (Annex 4.1).
- During the CHMP meeting on 13-16 November 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant (Annex 4.2).
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 12 January 2007 (Annex 4.3)
- During the meeting on 22-24 January 2007, the CHMP, in light of the overall data submitted and  the  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a  Marketing Authorisation to Xelevia on 24 January 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 January 2007 (Annex 4.4).